| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About | |
Adjunct CellCept (mycophenolate mofetil) with Reduced Corticosteroids in Subjects with Myasthenia Gravis
This study is currently recruiting patients.
| Sponsored by: | Hoffmann-La Roche
as part of the Aspreva Rare Disease Program
|
|---|---|
| Information provided by: | Hoffmann-La Roche |
Purpose
Myasthenia gravis is a rare, debilitating neurological autoimmune disease. Mycophenolate mofetil (MMF) modulates autoimmune responses through a unique mode of action which may be relevant for autoimmune disease patients. This study will test the safety and efficacy of adjunct MMF to maintain or improve symptom control with reduced corticosteroids in subjects with myasthenia gravis.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Myasthenia Gravis |
Drug: mycophenolate mofetil |
Phase III |
MedlinePlus related topics: Myasthenia Gravis
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, 36-week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symptom Control with Reduced Corticosteroids in Subjects with Myasthenia Gravis
Expected Total Enrollment: 136
Study start: March 2004
Eligibility
Ages Eligible for Study: 18 Years - 80 Years, Genders Eligible for Study: Both
Criteria
Major Inclusion Criteria:
Major Exclusion Criteria:
Location
and Contact
Information
More Information
 | ||||||||||||||
| U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
| National Institutes of Health, Department of Health & Human Services | ||||||||||||||
| Copyright, Privacy, Accessibility, Freedom of Information Act | ||||||||||||||